Form 4: Medifast Director Parsa Kiai Receives Equity Compensation

Director Parsa Kiai acquired 19,317 shares of Medifast, Inc. common stock as part of his annual director compensation package.

Summary

• Director Parsa Kiai was granted 11,680 restricted stock units (RSUs) as part of the Director's Deferred Compensation Plan.
• The director elected to receive an additional 7,637 shares of common stock in lieu of cash compensation for his annual service.
• The total acquisition of 19,317 shares brings the director's direct beneficial ownership to 19,317 shares.
• The RSUs are scheduled to vest in full on May 26, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Director demonstrated confidence in the company by electing to receive stock in lieu of cash fees.

Negatives

• None identified.

Risks

• Vesting conditions for the 11,680 RSUs are subject to the terms of the 2012 Share Incentive Plan.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Management Comments

• The transaction reflects the standard annual compensation process for non-employee directors under the company's established deferred compensation plan.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice designed to align director incentives with long-term shareholder value, particularly in the consumer health and wellness sector.

Comparison to Industry Standards

• The use of stock-in-lieu-of-cash for director fees is a common practice among mid-cap companies to preserve cash flow.
• The vesting period of one year for director RSUs is consistent with standard industry practices for board compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; represents standard director compensation dilution.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of 11,680 restricted stock units on May 26, 2027.

Key Dates

Keywords

Medifast, MED, Form 4, Director Compensation, Insider Trading, Equity Grant